Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the GUCY2D gene.
Features include always present findings: Nyctalopia, Reduced visual acuity, Dyschromatopsia, and Chorioretinal atrophy; and very common findings: Macular atrophy. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Nystagmus, Progressive night blindness, Macular atrophy |
GUCY2D encodes guanylate cyclase 2D, retinal (1,103 aa). Catalyzes the synthesis of cyclic GMP (cGMP) in rods and cones of photoreceptors. Plays an essential role in phototransduction, by mediating cGMP replenishment. Highest expression in Testis (2.4 TPM) and Esophagus Mucosa (0.7 TPM).
Cone-rod dystrophy 6 is associated with mutations in the GUCY2D gene on chromosome 17.
The GUCY2D protein participates in GUCYs converts GTP to cGMP pathway.
GUCY2D is classified as a druggable target (Druggable Genome, Enzyme, Kinase, and Transporter categories) with score 17.4.
Genetic testing for GUCY2D is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone-rod dystrophy 6 has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 1 very common feature, 2 common features.
No clinical trials have been registered for cone-rod dystrophy 6.
13 publications have been identified in PubMed for cone-rod dystrophy 6. Research spans Epidemiology / Natural History (31%), Basic Science / Preclinical (23%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 4 | 31% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 2:26 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 6
2 |
Macular atrophy, Chorioretinal atrophy |
Bones and joints | 1 | Bone spicule pigmentation of the retina |
3 |
23% |
Testing and diagnosis research | 2 | 15% |
Research summaries | 2 | 15% |
Patient case studies | 2 | 15% |
Sato S (2026). [PMID: 42045071](https://pubmed.ncbi.nlm.nih.gov/42045071/). *J Neurosci*. [Basic Science / Preclinical]
Demirkol A (2026). [PMID: 41751276](https://pubmed.ncbi.nlm.nih.gov/41751276/). *Biomedicines*. [Diagnostic / Biomarker]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *American journal of ophthalmology*. [Epidemiology / Natural History]
Lähteenoja L (2025). [PMID: 40571344](https://pubmed.ncbi.nlm.nih.gov/40571344/). *The British journal of ophthalmology*. [Review / Meta-Analysis]
Sanders F (2025). [PMID: 40541286](https://pubmed.ncbi.nlm.nih.gov/40541286/). *The British journal of ophthalmology*. [Epidemiology / Natural History]
Liu C (2025). [PMID: 41153400](https://pubmed.ncbi.nlm.nih.gov/41153400/). *Genes*. [Diagnostic / Biomarker]
Sao Su S (2025). [PMID: 40101946](https://pubmed.ncbi.nlm.nih.gov/40101946/). *Ophthalmic genetics*. [Epidemiology / Natural History]
Guareschi BLV (2025). [PMID: 41012804](https://pubmed.ncbi.nlm.nih.gov/41012804/). *Veterinary sciences*. [Basic Science / Preclinical]
Dizhoor AM (2025). [PMID: 39909376](https://pubmed.ncbi.nlm.nih.gov/39909376/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
Fang XH (2025). [PMID: 40688792](https://pubmed.ncbi.nlm.nih.gov/40688792/). *International journal of ophthalmology*. [Review / Meta-Analysis]